Ionis (IONS) Operating Margin

Official company branding of Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS) generates revenue based on royalties and licenses from the development of drugs targeting genetic pathologies. Operating profit margins reflect the model's reaction to external challenges, where -58.90 indicates the current level. Business stability relies on external partner plants, while an active R&D pipeline of RNA therapies provides record growth potential.

IONS - Ionis Pharmaceuticals, Inc. Operating Margin over the range 07/04/2022 - 11/19/2026

IONS (Ionis Pharmaceuticals): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Comprehensive company analysis:Ionis Pharmaceuticals, Inc., IONS
Finished products of Isis Pharmaceuticals

Operating margin is calculated as the ratio of operating profit to total revenue, measuring cost management efficiency before accounting for financial and tax obligations. This metric reflects the ability of Ionis Pharmaceuticals (IONS) to convert RNA therapy sales into actual income during the portfolio scaling phase, allowing for an assessment of the business model's sustainability through the recorded operating margin.

Main competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Profitability Repligen Corp (RGEN)|RNA - Operating Return on Sales|crisprtx.com - Operating Sales Margin|Operating Profit Rate WGS|RARE - Operating Profitability|Beam Tx (BEAM) - Operating Sales Margin|SRPT (Sarepta Therapeutics Inc) - Operating Sales Margin|TWST: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability